Sign in Subscribe

Industry News

M&A, deals, financial results, company news

Alzheimer’s disease : Beyond the beta amyloid hypothesis

Alzheimer’s disease : Beyond the beta amyloid hypothesis

SPECIAL REPORT 25.4 Scientific publication This article which was published in a different format in the February 2025 issue of MedNous presents work underway on candidate diagnostics, new concepts and late-stage therapies, to deliver a new generation of Alzheimer’s treatments. Learn more Summary Alzheimer’s disease is a

US FDA Novel Drug Approval for 2024.

US FDA Novel Drug Approval for 2024.

SPECIAL REPORT 25.1 We wish all our readers and followers a Happy and Prosperous Year 2025 US FDA Novel Drug Approval for 2024.The latest report issued by the FDA’s Center for Drug Evaluation and Research (CDER) indicates that the US health agency has approved 50 novel drugs

EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease

EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease

SPECIAL REPORT 24.15 On July 25, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended against marketing authorisation of BioArtic, Eisai and Biogen’s Lequembi, or lecanemab, an amyloid antibody for the treatment ofAlzheimer’s disease. After re-examining its initial opinion, EMA’

Une approche diagnostique holistique de la maladie d’Alzheimer.

Une approche diagnostique holistique de la maladie d’Alzheimer.

SPECIAL REPORT 24.13 La maladie d’Alzheimer reste une pathologie très complexe qui probablement ne se vaincra pas par la découverte d’un vaccin miracle comme on l’espérait en 1999, après la publication dans Nature d’une étude menée par Dale Shenk. Pendant près de trois décennies la

UK approves Kisunla for the treatment of Alzheimer’s disease but NICE …does not pay for it.

UK approves Kisunla for the treatment of Alzheimer’s disease but NICE …does not pay for it.

SPECIAL REPORT 24.12 On October 23, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the licensing of Eli Lilly’s Donanemab or Kisunla for the treatment of early stage Alzheimer’s disease, but the health technology agency National Institute for Health and Care Excellence (NICE) said

Current Leading Biopharmaceutical Products by Sales

Current Leading Biopharmaceutical Products by Sales

This document has been prepared by Jean-Claude Muller and is provided for information purposes only. The information contained herein has been obtained from sources believed to be reliable but is not warranted to be accurate or complete. The views presented are those of the author at the time of writing